Navigation Links
Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim
Date:9/26/2010

MELBOURNE, Australia, Sept. 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its biosimilar filgrastim product, Nivestim™.

Nivestim has been approved for a range of indications, including the prevention of febrile neutropenia (FN) and reduction in duration of chemotherapy-induced neutropenia (CIN). Neutropenia is the most serious hematological toxicity that occurs as a result of cancer chemotherapy and can lead to chemotherapy dose reductions and/or dose delays compared with the prescribed schedule.(1)

Nivestim is the first biosimilar version of Neupogen® approved in Australia. Neupogen has current sales within Australia of approximately AUD25 million (U.S. $24 million). Hospira is working closely with Australian government agencies to ensure efficient market access for biosimilars, and has submitted an application to have Nivestim listed on the Australian Pharmaceutical Benefits Scheme. Listing and product launch are expected during the first half of 2011.

"Approval of Nivestim, the first biosimilar filgrastim in Australia, is another important milestone for Hospira as we build our global biosimilars portfolio," said Tim Oldham, president, Asia Pacific, Hospira. "Nivestim will help reduce the cost of providing this lifesaving therapy across Australia, and includes a unique combination of administration, storage and safety features that will enhance safety for healthcare professionals and patients."

Three pre-filled syringe presentations of Nivestim were approved in Australia: 300 mcg/0.5 mL, 480 mcg/0.5 mL and a unique 120 mcg/0.2 mL low body weight presentation.

In a large, randomized Phase lll study, Nivestim demonstrated comparable efficacy to Neupogen in the prevention of FN, and was as well tolerated, with a similar adverse event profile.(2)

Nivestim is Hospira's second biosimilar and first in Australia. The company's biosimilar erythropoietin, Retacrit™, is currently available in 17 European countries, and Nivestim was approved by the European Commission in June 2010.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. The head office for Hospira in the Asia Pacific region is in Melbourne, Australia. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Hospira's goals with respect to Nivestim. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission and subsequently filed Quarterly Reports on Form 10-Q, which are  incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

(1) Crawford J, Dale DC, Lyman GH. Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management. Cancer, 2004; 100(2): 228-37

(2) Waller, CF et al. Biosimilar filgrastim is an effective primary prophylactic therapy for neutropenia in patients (pts) receiving doxorubicin and docetaxel (AT) for breast cancer (BC). Poster presentation at the joint ECCO 15 and 34th ESMO Multidisciplinary Congress: Abstract E15-1238, 2009.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
2. Hospira Announces CEO Succession Plan
3. Hospira to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Aug. 12
4. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
5. Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections
6. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
7. Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
8. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
9. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
10. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
11. Hospira to Present at Citi 2010 Global Health Care Conference May 27, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25, 2016  Zymo Research Corp. announced today ... reference materials that help researchers obtain the most ... analyses. The rapid growth of the study of ... have standard methods to improve the reproducibility and ... exist at every step of the measurement process ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... 25, 2016 MedDay, a biotechnology company ... an oral presentation entitled "High doses of biotin in progressive ... be given by Professor Ayman Tourbah , Principal Investigator ... the European Academy of Neurology (EAN) in Copenhagen, ... 3" will take place on Sunday, 29 May 2016 from ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 26, 2016 , ... MadgeTech will be showcasing its line of data ... Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries around ... including NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will ... Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public ... Retina Group of New York , is a Board Certified ophthalmologist who ...
(Date:5/26/2016)... Angeles, CA (PRWEB) , ... May 26, 2016 , ... In an effort to provide ... videos available to both Snapchat users and those who do not use the app. Dr. ... on his new page, Dr. Mohebi Live . , Dr. Mohebi says, “The ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of healthcare supply chain solutions, today announced the organization has earned its ISO ... international standards and is compliant with all rules and policies associated with ISO ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The Lung ... host a six-week smoking cessation class starting June 6 at their clinic in downtown ... http://www.gnahec.org . , Additionally, the Lung Institute has created a free downloadable 4 Week ...
Breaking Medicine News(10 mins):